BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Leng Y, Huang W, Ren G, Cai C, Tan Q, Liang Y, Yang W, Gao Z. The treatment and risk factors of retinopathy of prematurity in neonatal intensive care units. BMC Ophthalmol 2018;18:301. [PMID: 30458733 DOI: 10.1186/s12886-018-0973-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Vural A, Gunay M, Celik G, Demirayak B, Kizilay O. Comparison of foveal optical coherence tomography angiography findings between premature children with ROP and non-premature healthy children. Eye (Lond) 2021;35:1721-9. [PMID: 32873943 DOI: 10.1038/s41433-020-01161-x] [Reference Citation Analysis]
2 Solans Pérez de Larraya AM, Ortega Molina JM, Uberos Fernández J, González Ramírez AR, García Serrano JL. Speed of Retinal Vascularization in Retinopathy of Prematurity: Risk and Protective Factors. Biomed Res Int 2019;2019:2721578. [PMID: 31231670 DOI: 10.1155/2019/2721578] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
3 Kindinger LM, David AL. The role of the obstetrician in the prevention of retinopathy of prematurity. Semin Perinatol 2019;43:323-32. [PMID: 31174873 DOI: 10.1053/j.semperi.2019.05.003] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Chang ET, Josan AS, Purohit R, Patel CK, Xue K. A Network Meta-Analysis of Retreatment Rates following Bevacizumab, Ranibizumab, Aflibercept and Laser for Retinopathy of Prematurity. Ophthalmology 2022:S0161-6420(22)00522-X. [PMID: 35842190 DOI: 10.1016/j.ophtha.2022.06.042] [Reference Citation Analysis]
5 Wang Y, Long W, Cao Y, Li J, You L, Fan Y. Mesenchymal stem cell-derived secretomes for therapeutic potential of premature infant diseases. Biosci Rep 2020;40:BSR20200241. [PMID: 32320046 DOI: 10.1042/BSR20200241] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
6 Bahmani T, Karimi A, Rezaei N, Daliri S. Retinopathy prematurity: a systematic review and meta-analysis study based on neonatal and maternal risk factors. J Matern Fetal Neonatal Med 2021;:1-19. [PMID: 34256661 DOI: 10.1080/14767058.2021.1940938] [Reference Citation Analysis]
7 Popovic MM, Nichani P, Muni RH, Mireskandari K, Tehrani NN, Kertes PJ. Intravitreal antivascular endothelial growth factor injection versus laser photocoagulation for retinopathy of prematurity: A meta-analysis of 3,701 eyes. Surv Ophthalmol 2021;66:572-84. [PMID: 33338470 DOI: 10.1016/j.survophthal.2020.12.002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Ni YQ, Xu SS, Zhang T, Huang X. Clinical features and changes of disease spectrum of zone II retinopathy of prematurity: a 10-year review. Int J Ophthalmol 2020;13:1753-7. [PMID: 33215006 DOI: 10.18240/ijo.2020.11.11] [Reference Citation Analysis]
9 Tsai AS, Chou HD, Ling XC, Al-Khaled T, Valikodath N, Cole E, Yap VL, Chiang MF, Chan RVP, Wu WC. Assessment and management of retinopathy of prematurity in the era of anti-vascular endothelial growth factor (VEGF). Prog Retin Eye Res 2021;:101018. [PMID: 34763060 DOI: 10.1016/j.preteyeres.2021.101018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
10 Chaubey S, Bhandari V. Stem Cells in Neonatal Diseases: An Overview. Seminars in Fetal and Neonatal Medicine 2022. [DOI: 10.1016/j.siny.2022.101325] [Reference Citation Analysis]